2021-11-12T11:49:23-06:00 2020-12-31 042571780 AAFCPAS INC 50 WASHINGTON STREET WESTBOROUGH MA 01581 990 2020-01-01 043462719 ALS THERAPY DEVELOPMENT FOUNDATION INC D/B/A ALS THERAPY DEVELOPMENT INSTITUTE ALST 6174417200 480 ARSENAL STREET SUITE 201 WATERTOWN MA 02472 FERNANDO VIEIRA CHIEF SCIENTIFIC OFFICER 6174417200 2021-11-10 1 FERNANDO VIEIRA XXX-XX-XXXX COURTNEY MCFARLAND CPA P01645518 5083669100 2021-11-10 2 AAL1 IAL1 2020 2022-09-23 18:48:47Z STEVE PERRIN 480 ARSENAL STREET SUITE 201 WATERTOWN MA 02472 18247216 0 X WWW.ALS.NET X 1999 MA WE ARE COMMITTED TO CREATING AND LEADING A TRANSPARENT COLLABORATIVE RESEARCH PROCESS THAT INVOLVES ALS PATIENTS TODAY AND HONORS THOSE WHOSE JOURNEY WITH THIS DISEASE HAS ENDED. WE ARE GUIDED BY PASSION, LOVE AND THE SPIRIT OF ENTREPRENEURSHIP UPON WHICH WE WERE FOUNDED. 18 18 57 500 0 0 11823260 8062216 410883 265315 50014 1118667 845579 802415 13129736 10248613 0 0 0 0 5025290 4424215 253000 0 278666 6180600 5105092 11458890 9529307 1670846 719306 17469547 29996989 2379417 2792824 15090130 27204165 OUR MISSION IS TO IDENTIFY VIABLE TARGETS FOR THERAPY DEVELOPMENT AND EXPEDITIOUSLY MANAGE THE CREATION OF THOSE TREATMENTS THAT WILL ARREST THE SUFFERING OF TODAY'S ALS PATIENTS. 0 0 8425564 355332 ALS TDI COMBINES THE PASSION AND DEDICATION OF A NONPROFIT ORGANIZATION WITH THE ENTREPRENEURIAL AND SCIENTIFIC SPIRIT OF A BIOTECHNOLOGY COMPANY. OUR LABORATORY IS THE LEADING DRUG DISCOVERY PROGRAM FOR ALS, AND IT BRIDGES A CRITICAL RESEARCH GAP. OUR IN-HOUSE EXPERTISE TRANSLATES RESEARCH INTO POTENTIAL DRUG CANDIDATES BY SCREENING DRUGS IN THE SOD1 MOUSE MODEL OF ALS. OUR SCIENTIFIC COLLABORATIONS ARE DESIGNED TO BRING THE MOST PROMISING LEADS CLOSER TO PATIENT USE. WE SHARE EMERGING KNOWLEDGE ON THE DISEASE WITH PATIENTS, PHYSICIANS, AND RESEARCHERS AS QUICKLY AND COMPREHENSIVELY AS POSSIBLE. EVERY DECISION IS MADE IN THE INTEREST OF FINDING EFFECTIVE TREATMENTS FOR PEOPLE LIVING WITH ALS. OUR UNIQUE APPROACH ACCELERATES DRUG DEVELOPMENT FOR ALS. 8425564 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 1 1 1 0 0 1 10 0 1 57 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 18 18 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 1 1 AL AK AZ AR CA CO CT DE FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC TN TX SD UT VT VA WA WV WY WI X X INSOURCE SERVICES INC 7812351490 148 LINDEN STREET WELLESLEY MA 02482 X DR STANLEY H APPEL MD BOARD MEMBER 2.50 X 0 0 0 ALEXANDER CAPPELLO BOARD MEMBER 2.50 X 0 0 0 DR SPIROS JAMAS SCD BOARD MEMBER 2.50 X 0 0 0 KEITH MELANSON BOARD MEMBER 2.50 X 0 0 0 LESLIE MICHELSON JD BOARD MEMBER 2.50 X 0 0 0 JOHN B HEYWOOD PHD SCD BOARD MEMBER 2.50 X 0 0 0 AUGIE NIETO BOARD MEMBER 2.50 X 0 0 0 ROB RODIN CHAIRMAN AND BOARD MEMBER 2.50 X X 0 0 0 STEVEN PERRIN PHD CEO/PRESIDENT AND SECRETARY 20.00 20.00 X X 0 0 0 JAMES ALLEN HEYWOOD BOARD MEMBER 2.50 X 0 0 0 THEODORE REICH JD CPA TREASURER AND BOARD MEMBER 2.50 X X 0 0 0 ROBERT SEPUCHA BOARD MEMBER 2.50 X 0 0 0 JENNY DWYER BOARD MEMBER 2.50 X 0 0 0 MIKE SMITH BOARD MEMBER 2.50 X 0 0 0 LYNNE NIETO BOARD MEMBER 2.50 X 0 0 0 JULIE SWAN BOARD MEMBER 2.50 X 0 0 0 ERIC S CRAVEN BOARD MEMBER (UNTIL 4/2020) 2.50 X 0 0 0 KENT JACKSON BRANSFORD MD BOARD MEMBER 2.50 X 0 0 0 ANDREW NIBLOCK BOARD MEMBER 2.50 X 0 0 0 ALAN GILL VP OF RESEARCH 40.00 X 176211 0 13229 MATVEY LUKASHEV VP OF TRANSLATIONAL SCIENCES 40.00 X 174637 0 6813 FERNANDO VIEIRA CHIEF SCIENTIFIC OFFICER 40.00 X 243145 0 19220 BASHAR AL-NAKHALA CHIEF OPERATING OFFICER 40.00 X 200994 0 20220 THEO HATZIPETROS DIRECTOR OF PHARMACOLOGY 40.00 X 121047 0 20220 916034 0 79702 11 0 1 0 INSOURCE SERVICES INC PO BOX 427 NEWTON UPPER FALLS MA 02464 FINANCE, HR & IT 305056 NELSON MULLINS POST OFFICE DRAWER 11009 COLUMBIA SC 29211 LEGAL 124378 HONIGMAN MILLER SCHWARTZ AND COHN LLP 315 EAST EISENHOWER PARKWAY SUITE ANN ARBOR MI 48108 LEGAL 123456 3 4141709 3920507 2481 8062216 PHARMACEUTICAL CONTRACTS 541700 265315 265315 265315 17725 17725 9019280 7918338 1100942 1100942 1100942 792663 4141709 80265 712398 712398 CONTRACTED SERVICES 541900 90017 90017 90017 10248613 355332 0 1831065 3540039 3161389 255134 123516 36957 31414 2217 3326 573358 509172 46523 17663 273861 244532 19741 9588 242682 242682 53807 53807 434011 406779 27232 114002 102603 464 10935 374630 345729 5123 23778 2316781 2218483 94790 3508 25512 25512 10679 10679 234100 208903 16979 8218 41229 38426 2803 TESTING AND LAB EXPENSE 1099489 1099489 BANK AND CREDIT CARD PR 61426 3200 58226 MISCELLANEOUS 52518 11507 41011 FUNDRAISING 19772 19772 24454 21626 2692 136 9529307 8425564 825077 278666 3133540 4667402 3407029 3080830 495098 255000 876984 206940 474042 382139 3123351 2840371 334061 282980 20414009 580456 707689 8168337 0 17469547 29996989 711917 293124 40472 2495 1042895 84150 95059 896400 499983 1505746 2379417 2792824 X 14519380 26954165 570750 250000 15090130 27204165 17469547 29996989 719306 11394729 0 X X 0 1 X 1 0 X 10283977 14163205 12729824 11823260 8062216 57062482 10283977 14163205 12729824 11823260 8062216 57062482 4359178 52703304 6115 9636 34605 50014 17725 118095 185963 292007 396903 279636 90017 1244526 58425103 4876314 0.90210 0.88510 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: OTHER INCOME RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 0 375683 375683 0 2747668 2464688 282980 282980 DEFERRED RENT LIABILITY 1505746 1505746 X 21683826 11394729 40484 11435213 10248613 0 10248613 9569791 40484 40484 9529307 0 9529307 PART X, LINE 2: ALS TDI ACCOUNTS FOR UNCERTAINTY IN INCOME TAXES IN ACCORDANCE WITH ASC TOPIC, INCOME TAXES. THIS STANDARD CLARIFIES THE ACCOUNTING FOR UNCERTAINTY IN TAX POSITIONS AND PRESCRIBES A RECOGNITION THRESHOLD AND MEASUREMENT ATTRIBUTE FOR THE FINANCIAL STATEMENTS REGARDING A TAX POSITION TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN. ALS TDI HAS DETERMINED THAT THERE ARE NO UNCERTAIN TAX POSITIONS WHICH QUALIFY FOR EITHER RECOGNITION OR DISCLOSURE IN THEIR FINANCIAL STATEMENTS AT DECEMBER 31, 2020. THE INFORMATIONAL RETURNS OF ALS TDI ARE SUBJECT TO EXAMINATION BY THE FEDERAL AND STATE JURISDICTIONS AND GENERALLY REMAIN OPEN FOR THE MOST RECENT THREE YEARS. VIRTUAL TREK 472077 9974 462103 1264 8710 VIRTUAL WHITE COAT AFFAIR 317819 0 317819 10795 95 1 4144476 4131735 12741 59401 4934372 4141709 792663 10795 1264 68206 80265 712398 X X X X 0 0 0 0 0 0 0 0 0 FERNANDO VIEIRA CHIEF SCIENTIFIC OFFICER 243145 0 0 0 0 0 0 0 19220 0 262365 0 0 0 BASHAR AL-NAKHALA CHIEF OPERATING OFFICER 200994 0 0 0 0 0 0 0 20220 0 221214 0 0 0 ALAN GILL VP OF RESEARCH 176211 0 0 0 0 0 0 0 13229 0 189440 0 0 0 MATVEY LUKASHEV VP OF TRANSLATIONAL SCIENCES 174637 0 0 0 0 0 0 0 6813 0 181450 0 0 0 ANELIXIS THERAPEUTICS INC SUBSIDIARY 58686 CERTAIN EMPLOYEES OF ALS TDI SPENT A PORTION OF THEIR TIME PERFORMING SERVICES FOR ANELIXIS PHARMACEUTICALS, INC. DURING TAX YEAR 2020. ALS TDI HAS CHARGED ANELIXIS PHARMACEUTICALS, INC. FOR THESE SERVICES, EQUAL TO THE COST INCURRED BY ALS TDI FOR SALARY AND RELATED COSTS RELATING TO THESE EMPLOYEES. 0 FORM 990, PART VI, SECTION A, LINE 2 JAMES HEYWOOD, BOARD MEMBER, IS THE SON OF JOHN HEYWOOD, MEMBER OF THE BOARD OF DIRECTORS. ADDITIONALLY, LYNNE NIETO AND KENT BRANSFORD, BOARD MEMBERS, ARE THE WIFE AND BROTHER-IN-LAW, RESPECTIVELY, OF AUGIE NIETO, BOARD MEMBER. FORM 990, PART VI, SECTION B, LINE 11B FORM 990 IS REVIEWED BY THE CHIEF FINANCIAL OFFICER AND THEN APPROVED BY THE BOARD OF DIRECTORS. FORM 990, PART VI, SECTION B, LINE 12C ALS TDI HAS A WRITTEN CONFLICT OF INEREST POLICY WHICH REQUIRES ANNUAL SIGNOFFS BY OFFICERS, DIRECTORS AND KEY EMPLOYEES. FORM 990, PART VI, SECTION B, LINE 15 THE PROCESS TO DETERMINE THE COMPENSATION OF THE PRESIDENT CONSISTS OF EVALUATING COMPARABLE DATA FOR FUNCTIONALLY SIMILAR POSITIONS AT SIMILAR ORGANIZATIONS, ALONG WITH THE REVIEW AND APPROVAL BY THE EXECUTIVE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS WHICH IS COMPRISED OF INDEPENDENT MEMBERS. FORM 990, PART VI, SECTION B, LINE 15B: THE PROCESS TO ESTABLISH COMPENSATION OF OTHER OFFICERS AND KEY EMPLOYEES IS COMPLETED ON AN ANNUAL BASIS BY EVALUATING COMPARABLE DATA FOR FUNCTIONALLY SIMILAR POSITIONS AT SIMILAR ORGANIZATIONS, PRESENTING RECOMMENDATIONS TO THE EXECUTIVE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS WHICH IS COMPRISED OF INDEPENDENT MEMBERS AND DOCUMENTING SUCH DISCUSSIONS IN THE BOARD MINUTES. FORM 990, PART VI, SECTION C, LINE 18 ALS TDI'S FORM 990 IS AVAILABLE FOR PUBLIC INSPECTION ON ALS TDI'S WEBSITE AND AT WWW.GUIDESTAR.COM. ALS TDI'S FORM 1023 IS AVAILABLE UPON REQUEST. FORM 990, PART VI, SECTION C, LINE 19 FINANCIAL STATEMENTS ARE MADE AVAILABLE ON ALS TDI'S WEB SITE AND ARE AVAILABLE BY MAIL UPON REQUEST. GOVERNING DOCUMENTS AND ALS TDI'S CONFLICT OF INTEREST POLICY ARE AVAILABLE UPON REQUEST. FORM 990, PART XII, LINE 2C: DURING 2020, THE ORGANIZATION DID NOT CHANGE THE WAY IN WHICH ITS COMMITTEE ASSUMES RESPONSIBILITY FOR OVERSIGHT OF THE AUDIT, ITS FINANCIAL STATEMENTS, AND SELECTION OF AN INDEPENDENT ACCOUNTANT. FORM 990, PART VI, SECTION B, LINE 16: ALS TDI'S POLICY OVER EVALUATING ITS PARTICIPATION IN ITS JOINT VENTURE WITH ANELIXIS PHARMACEUTICALS, INC., INVOLVED AN ASSESSMENT PERFORMED BY MANAGEMENT AND THE BOARD OF DIRECTORS TO ENSURE THE TERMS OF THE ARRANGEMENT WAS PERMITTED UNDER APPLICABLE FEDERAL TAX LAW AND ALS TDI'S EXEMPT STATUS IS BEING SAFEGUARDED. AS OF DECEMBER 31, 2020 ALS TDI SOLD ALL OF THEIR SHARES OF ANELIXIS PHARMACEUTICALS. ANELIXIS PHARMACEUTICALS INC 300 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 474022454 GENERATE CAPITAL FROM INVESTORS TO SUPPORT DISCOVERIES AND PATENTS RELATED T DE ALS TDI C 1 1 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 1 1 ANELIXIS PHARMACEUTICALS INC L 58686 COST